{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Riboflavin&page=2",
    "query": {
      "intervention": "Riboflavin",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Riboflavin&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T18:30:37.772Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04843046",
      "title": "Pioglitazone as an Adjunct to Cognitive-Behavioral Therapy for Cocaine Relapse Prevention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cocaine Use Disorder"
      ],
      "interventions": [
        {
          "name": "Cognitive Behavioral Therapy (CBT)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 61,
      "start_date": "2021-08-23",
      "completion_date": "2025-10-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-09-25T18:30:37.772Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04843046"
    },
    {
      "nct_id": "NCT01582880",
      "title": "Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chemical Injuries",
        "Unspecified Complication of Corneal Transplant",
        "Autoimmune Diseases",
        "Ocular Cicatricial Pemphigoid",
        "Stevens Johnson Syndrome",
        "Lupus Erythematosus, Systemic",
        "Rheumatoid Arthritis",
        "Other Autoimmune Diseases"
      ],
      "interventions": [
        {
          "name": "Riboflavin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Joseph B. Ciolino, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2012-03",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2019-10-21",
      "last_synced_at": "2026-09-25T18:30:37.772Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01582880"
    },
    {
      "nct_id": "NCT01726283",
      "title": "Combined CXL//UV and PRK or LASIK in Forme Fruste Keratoconus or Eyes With Potential Risk of Ectasia",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fruste Keratoconus",
        "Risk of Ectasia"
      ],
      "interventions": [
        {
          "name": "Corneal Cross-Linking",
          "type": "DEVICE"
        },
        {
          "name": "Riboflavin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Cxlusa",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2011-10",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2015-08-24",
      "last_synced_at": "2026-09-25T18:30:37.772Z",
      "location_count": 8,
      "location_summary": "Scottsdale, Arizona • San Diego, California • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Waltham",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01726283"
    },
    {
      "nct_id": "NCT02235337",
      "title": "The Impact of Riboflavin on the Severity and Duration of Sports Related Concussion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sports Related Concussion"
      ],
      "interventions": [
        {
          "name": "Riboflavin 400mg daily",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 248,
      "start_date": "2014-09",
      "completion_date": "2015-08",
      "has_results": false,
      "last_update_posted_date": "2017-08-11",
      "last_synced_at": "2026-09-25T18:30:37.772Z",
      "location_count": 2,
      "location_summary": "Charlottesville, Virginia • Harrisonburg, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        },
        {
          "city": "Harrisonburg",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02235337"
    },
    {
      "nct_id": "NCT01893359",
      "title": "Safety and Efficacy of Corneal Collagen Cross-linking Following LASIK for Treatment of Hyperopia and Hyperopic Astigmatism",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hyperopia",
        "Hyperopic Astigmatism"
      ],
      "interventions": [
        {
          "name": "riboflavin ophthalmic solution, 0% dextran",
          "type": "DRUG"
        },
        {
          "name": "UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA)",
          "type": "DEVICE"
        },
        {
          "name": "UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off)",
          "type": "DEVICE"
        },
        {
          "name": "Laser-assisted in situ keratomileusis",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Glaukos Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2013-08",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2021-04-26",
      "last_synced_at": "2026-09-25T18:30:37.772Z",
      "location_count": 5,
      "location_summary": "San Diego, California • Waltham, Massachusetts • Teaneck, New Jersey + 2 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Waltham",
          "state": "Massachusetts"
        },
        {
          "city": "Teaneck",
          "state": "New Jersey"
        },
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        },
        {
          "city": "McLean",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01893359"
    },
    {
      "nct_id": "NCT04708340",
      "title": "Tolerability and Efficacy of RJX in Patients With COVID-19",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "COVID-19",
        "Acute Respiratory Distress Syndrome",
        "SARS-CoV-2",
        "Hypoxemia"
      ],
      "interventions": [
        {
          "name": "Rejuveinix (RJX) Active Comparator",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Reven Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 237,
      "start_date": "2021-03-25",
      "completion_date": "2023-02",
      "has_results": false,
      "last_update_posted_date": "2022-03-15",
      "last_synced_at": "2026-09-25T18:30:37.772Z",
      "location_count": 3,
      "location_summary": "Houston, Texas • New Braunfels, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "New Braunfels",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04708340"
    },
    {
      "nct_id": "NCT02773212",
      "title": "Targeting Anhedonia in Cocaine Use Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cocaine-Related Disorders",
        "Anhedonia"
      ],
      "interventions": [
        {
          "name": "d-amphetamine",
          "type": "DRUG"
        },
        {
          "name": "Contingency management",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Placebo (for d-amphetamine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 57,
      "start_date": "2017-02-01",
      "completion_date": "2022-04-04",
      "has_results": true,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-09-25T18:30:37.772Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02773212"
    },
    {
      "nct_id": "NCT06100952",
      "title": "Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Keratoconus"
      ],
      "interventions": [
        {
          "name": "Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo and sham treatment",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Epion Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "8 Years to 45 Years"
      },
      "enrollment_count": 398,
      "start_date": "2023-11-01",
      "completion_date": "2026-03-17",
      "has_results": false,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-09-25T18:30:37.772Z",
      "location_count": 12,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Murrieta, California + 9 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Murrieta",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Highland Park",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06100952"
    },
    {
      "nct_id": "NCT01474486",
      "title": "Feasibility and Effectiveness of Micronutrients as Palliative Care Therapy in Patients With Congestive Heart Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Congestive Heart Failure",
        "Ischemic Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "Micronutrients",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Phoenix VA Health Care System",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 40,
      "start_date": "2010-04",
      "completion_date": "2016-02",
      "has_results": true,
      "last_update_posted_date": "2021-06-10",
      "last_synced_at": "2026-09-25T18:30:37.772Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01474486"
    },
    {
      "nct_id": "NCT00044083",
      "title": "Clinical Trial of Tolcapone for Cognition in Schizophrenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Tolcapone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 210,
      "start_date": "2002-08",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2018-09-27",
      "last_synced_at": "2026-09-25T18:30:37.772Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00044083"
    }
  ]
}